C92.A
Acute myeloid leukemia with multilineage dysplasia
Clinical Classification Guidelines
Inclusion Terms
- Acute myeloid leukemia with dysplasia of remaining hematopoesis and/or myelodysplastic disease in its history
Medical Intelligence & Overview
Acute Myeloid Leukemia with Multilineage Dysplasia (AML-MDL), classified under ICD-10 code C92.A, is a specific type of leukemia characterized by the abnormal development of blood cells in the bone marrow. This condition involves not only rapid proliferation of immature white blood cells called myeloblasts but also abnormal development in multiple blood cell lineages, such as red blood cells and platelets. Often, it occurs in individuals with a history of myelodysplastic syndromes, which are disorders where blood cells are misshapen or dysfunctional. Recognizing this condition is crucial because it requires specialized management and has implications for prognosis.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting hematopoietic stem cells Prior exposure to chemotherapy or radiation therapy Pre-existing hematologic disorders, such as myelodysplastic syndromes Environmental factors like exposure to benzene or certain chemicals Age-related cellular changes and genetic predisposition
Key Symptoms: Fatigue and weakness due to anemia Unexplained fever and infections resulting from low white blood cell counts Bleeding or easy bruising caused by low platelet levels Fainting or shortness of breath Bone and joint pains Pallor and persistent infections Unintentional weight loss
Diagnostic & Treatment
Diagnosis Path: Diagnosing AML with multilineage dysplasia involves several steps including blood tests and bone marrow examination. The process usually includes: - **Blood tests** to identify abnormal blood cell counts and presence of immature cells - **Bone marrow biopsy and aspiration** to observe abnormal cell morphology and assess cellularity - **Cytogenetic analysis** to detect chromosomal abnormalities - **Immunophenotyping** via flow cytometry to classify the leukemia type - **Molecular testing** for genetic mutations that may influence treatment decisions. The combination of these investigations helps confirm the diagnosis and distinguish it from other hematologic disorders.
Treatment Protocols: Treatment for AML with multilineage dysplasia typically involves chemotherapy aimed at destroying cancerous cells, and may include additional therapies based on individual patient factors. Common approaches include: - **Induction chemotherapy** to induce remission - **Consolidation therapy** to prevent relapse, which may involve high-dose chemotherapy or hematopoietic stem cell transplantation - **Targeted therapies** if specific genetic mutations are present - **Supportive care** such as blood transfusions, antibiotics, and growth factors Due to the complexity of the disease, management is usually overseen by a specialized hematologist or oncologist. The treatment plan depends on various factors, including age, overall health, and specific genetic features of the leukemia.
Clinical Advice & FAQs
Billing Guidance
Is C92.A a billable ICD-10 code?
Yes, C92.A is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C92.A?
Clinical documentation must specify the nature of Acute myeloid leukemia with multilineage dysplasia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference